These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 39094579)

  • 1. Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination.
    Voss WN; Mallory MA; Byrne PO; Marchioni JM; Knudson SA; Powers JM; Leist SR; Dadonaite B; Townsend DR; Kain J; Huang Y; Satterwhite E; Castillo IN; Mattocks M; Paresi C; Munt JE; Scobey T; Seeger A; Premkumar L; Bloom JD; Georgiou G; McLellan JS; Baric RS; Lavinder JJ; Ippolito GC
    Cell Rep Med; 2024 Aug; 5(8):101668. PubMed ID: 39094579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in mice.
    Becker W; Rebbani K; Duan Z; Valkov E; Bryant S; Ho M; Berzofsky JA; Olkhanud PB
    Sci Rep; 2024 Nov; 14(1):29609. PubMed ID: 39609527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects.
    Jennewein MF; MacCamy AJ; Akins NR; Feng J; Homad LJ; Hurlburt NK; Seydoux E; Wan YH; Stuart AB; Edara VV; Floyd K; Vanderheiden A; Mascola JR; Doria-Rose N; Wang L; Yang ES; Chu HY; Torres JL; Ozorowski G; Ward AB; Whaley RE; Cohen KW; Pancera M; McElrath MJ; Englund JA; Finzi A; Suthar MS; McGuire AT; Stamatatos L
    Cell Rep; 2021 Jul; 36(2):109353. PubMed ID: 34237283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody response to SARS-CoV-2 mRNA vaccination in Danish adults exposed to perfluoroalkyl substances (PFASs): The ENFORCE study.
    Timmermann A; Johansen IS; Tolstrup M; Heilmann C; Budtz-Jørgensen E; Tolstrup JS; Nielsen F; Grandjean P
    Environ Res; 2024 Dec; 263(Pt 1):120039. PubMed ID: 39326653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.
    Zhu J; Wang Z; Li Y; Zhang Z; Ren S; Wang J; Xie S; Liao Z; Song B; Wu W; Yan F; Peng C
    J Virol; 2024 Jul; 98(7):e0052124. PubMed ID: 38874361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling serum immunodominance following SARS-CoV-2 primary and breakthrough infection reveals distinct variant-specific epitope usage and immune imprinting.
    Seow J; Jefferson GCE; Keegan MD; Yau Y; Snell LB; Doores KJ
    PLoS Pathog; 2024 Nov; 20(11):e1012724. PubMed ID: 39556615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saliva SARS-CoV-2 Antibody Prevalence in Children.
    Keuning MW; Grobben M; de Groen AC; Berman-de Jong EP; Bijlsma MW; Cohen S; Felderhof M; de Groof F; Molanus D; Oeij N; Rijpert M; van Eijk HWM; Koen G; van der Straten K; Oomen M; Visser R; Linty F; Steenhuis M; Vidarsson G; Rispens T; Plötz FB; van Gils MJ; Pajkrt D
    Microbiol Spectr; 2021 Oct; 9(2):e0073121. PubMed ID: 34523985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hybrid Immunity and SARS-CoV-2 Antibodies: Results of the HEROES-RECOVER Prospective Cohort Study.
    Romine JK; Li H; Coughlin MM; Jones JM; Britton A; Tyner HL; Fuller SB; Bloodworth R; Edwards LJ; Etolue JN; Morrill TC; Newes-Adeyi G; Olsho LEW; Gaglani M; Fowlkes A; Hollister J; Bedrick EJ; Uhrlaub JL; Beitel S; Sprissler RS; Lyski Z; Porter CJ; Rivers P; Lutrick K; Caban-Martinez AJ; Yoon SK; Phillips AL; Naleway AL; Burgess JL; Ellingson KD
    Clin Infect Dis; 2024 Jul; 79(1):96-107. PubMed ID: 38466720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of spike mutations on SARS-CoV-2 neutralization.
    Rees-Spear C; Muir L; Griffith SA; Heaney J; Aldon Y; Snitselaar JL; Thomas P; Graham C; Seow J; Lee N; Rosa A; Roustan C; Houlihan CF; Sanders RW; Gupta RK; Cherepanov P; Stauss HJ; Nastouli E; ; Doores KJ; van Gils MJ; McCoy LE
    Cell Rep; 2021 Mar; 34(12):108890. PubMed ID: 33713594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.
    Barnes CO; West AP; Huey-Tubman KE; Hoffmann MAG; Sharaf NG; Hoffman PR; Koranda N; Gristick HB; Gaebler C; Muecksch F; Lorenzi JCC; Finkin S; Hägglöf T; Hurley A; Millard KG; Weisblum Y; Schmidt F; Hatziioannou T; Bieniasz PD; Caskey M; Robbiani DF; Nussenzweig MC; Bjorkman PJ
    Cell; 2020 Aug; 182(4):828-842.e16. PubMed ID: 32645326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.
    Starr TN; Czudnochowski N; Liu Z; Zatta F; Park YJ; Addetia A; Pinto D; Beltramello M; Hernandez P; Greaney AJ; Marzi R; Glass WG; Zhang I; Dingens AS; Bowen JE; Tortorici MA; Walls AC; Wojcechowskyj JA; De Marco A; Rosen LE; Zhou J; Montiel-Ruiz M; Kaiser H; Dillen JR; Tucker H; Bassi J; Silacci-Fregni C; Housley MP; di Iulio J; Lombardo G; Agostini M; Sprugasci N; Culap K; Jaconi S; Meury M; Dellota E; Abdelnabi R; Foo SC; Cameroni E; Stumpf S; Croll TI; Nix JC; Havenar-Daughton C; Piccoli L; Benigni F; Neyts J; Telenti A; Lempp FA; Pizzuto MS; Chodera JD; Hebner CM; Virgin HW; Whelan SPJ; Veesler D; Corti D; Bloom JD; Snell G
    Nature; 2021 Sep; 597(7874):97-102. PubMed ID: 34261126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination.
    Wang M; Zhang L; Li Q; Wang B; Liang Z; Sun Y; Nie J; Wu J; Su X; Qu X; Li Y; Wang Y; Huang W
    Emerg Microbes Infect; 2022 Dec; 11(1):18-29. PubMed ID: 34818119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases.
    Anderson E; Powell M; Yang E; Kar A; Leung TM; Sison C; Steinberg R; Mims R; Choudhury A; Espinosa C; Zelmanovich J; Okoye NC; Choi EJ; Marder G; Narain S; Gregersen PK; Mackay M; Diamond B; Levy T; Zanos TP; Khosroshahi A; Sanz I; Luning Prak ET; Bar-Or A; Merrill J; Arriens C; Pardo G; Guthridge J; James J; Payne A; Utz PJ; Boss JM; Aranow C; Davidson A
    JCI Insight; 2024 Jun; 9(13):. PubMed ID: 38833310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hybrid response to SARS-CoV-2 and
    Portilho AI; Hermes Monteiro da Costa H; Grando Guereschi M; Prudencio CR; De Gaspari E
    Hum Vaccin Immunother; 2024 Dec; 20(1):2346963. PubMed ID: 38745461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries.
    Yuan TZ; Garg P; Wang L; Willis JR; Kwan E; Hernandez AGL; Tuscano E; Sever EN; Keane E; Soto C; Mucker EM; Fouch ME; Davidson E; Doranz BJ; Kailasan S; Aman MJ; Li H; Hooper JW; Saphire EO; Crowe JE; Liu Q; Axelrod F; Sato AK
    MAbs; 2022; 14(1):2002236. PubMed ID: 34967699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization.
    Gu M; Torres JL; Li Y; Van Ry A; Greenhouse J; Wallace S; Chiang CI; Pessaint L; Jackson AM; Porto M; Kar S; Li Y; Ward AB; Wang Y
    Emerg Microbes Infect; 2021 Dec; 10(1):2016-2029. PubMed ID: 34651563
    [No Abstract]   [Full Text] [Related]  

  • 19. Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination.
    Clark JJ; Hoxie I; Adelsberg DC; Sapse IA; Andreata-Santos R; Yong JS; Amanat F; Tcheou J; Raskin A; Singh G; González-Domínguez I; Edgar JE; Bournazos S; Sun W; Carreño JM; Simon V; Ellebedy AH; Bajic G; Krammer F
    Cell Rep; 2024 Nov; 43(11):114922. PubMed ID: 39504245
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.